Plastic Surgery Practice
  • Client Objectives
    • Aesthetics
    • Dermatology
    • Rejuvenation
  • Practice Management
    • Marketing
    • Office Management
    • Technology
  • Treatment Solutions
    • Innovations
    • Products
    • Pharmaceuticals
  • Resources
    • Podcasts
    • Videos
    • Webinars
    • White Papers

Select Page

Nestlé's Pharma Experiment Nears an End with $10B Skin Health Sale Talks

May 16, 2019 | Pharmaceuticals, Skin Conditions | 0 |

Just five years after Nestlé took full possession of dermatology specialist Galderma amid a pivot to pharma, the Swiss company is now in the final stage of bailing out of skin health as it refocuses on food and nutrition.
Nestlé has entered exclusive talks to sell its skin health unit to a consortium led by private equity EQT Partners for 10.2 billion Swiss francs ($10.1 billion), the company reports. The price tag is much higher than the previously rumored $7 billion.

Click here to view original web page at www.fiercepharma.com

Share:

Rate:

PreviousRealSelf Partners with The Aesthetic Society, Focuses on Patient Safety
NextSome Biologic Treatments for Psoriasis May Be Safer for Patients

Related Posts

Prolonged Breast-Feeding May Guard Against Teen Eczema

Prolonged Breast-Feeding May Guard Against Teen Eczema

November 14, 2017

Why You Shouldn’t Try Derma Rolling At Home

Why You Shouldn’t Try Derma Rolling At Home

April 4, 2017

PolarityTE Announces Presentations of SkinTE Clinical Results at Upcoming Plastic Surgery Conferences

PolarityTE Announces Presentations of SkinTE Clinical Results at Upcoming Plastic Surgery Conferences

September 28, 2018

Redefining Aesthetic Guidelines: Christian G. Drehsen, MD

Redefining Aesthetic Guidelines: Christian G. Drehsen, MD

February 8, 2013

Recent Posts

  • FDA Clears Suction-Based Device for Removal of Ruptured Breast Implants
    Feb 13, 2026 | Surgical Tools
  • Galderma Launches First OBT Hyaluronic Acid Injectables in Japan
    Feb 11, 2026 | Injectibles
  • How VYC-12L Performs in Treating Horizontal Neck Lines
    Feb 10, 2026 | Injectibles
  • AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib in Vitiligo
    Feb 9, 2026 | Skin Conditions
  • FDA Accepts Galderma’s BLA Resubmission for RelabotulinumtoxinA
    Feb 6, 2026 | Injectibles

Plastic Surgery Practice

7300 W 110th St – Floor 7
Overland Park, KS 66210
(913) 955-2600

Our Parent Company

MEDQOR LLC

About MEDQOR

MEDQOR Data Platform

Press Releases

Key Resources

Podcasts

Webinars

White Papers

Videos

Helpful Links

Media Solutions Kit

Subscribe Now

Contact Us

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

Copyright

Privacy Policy

Terms of Service

© 2024 MEDQOR LLC. All Rights Reserved